Form D · Biotechnology

Ultivue, Inc.

Cambridge, MA · CIK 0001651511

Offering snapshot reported Jul 25, 2024 · SEC filing

Reported sold
$3.32M
Offering amount: $15M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 11, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 25, 2024Initial$3,324,270No comparison5SEC filing
Jun 28, 2019Initial$26,502,993No comparison14SEC filing
Feb 1, 2018Amendment$20,249,996$10,148,028vs Jul 21, 201711SEC filing
Jul 21, 2017Initial$10,101,968No comparison6SEC filing
Aug 21, 2015Initial$5,150,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-519765

Source: Form D, filed Jul 25, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Carson Director, Executive
Wen Chen Director
Lian Yong Chen Director
Keith Crandell Director
Fenel Eloi Director
Andrea Jackson Director
Sharon Kedar Director
Michael Natan Director, Executive
Andrew Stevenson Director
David R. Walt Director
Peng Yin Director
Peng Ying Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
763 D Concord Ave.
Cambridge, MA, 02138